Dimerix Secures A$34 Million Non-Dilutive Facility for Clinical Milestones

Corporate Action
โดย PR Newswire·AU·Read original
Summary · why it matters

Dimerix Limited has secured non-dilutive loan facility agreements totaling A$34 million with a syndicate of Australian and U.S. lenders, including the previously announced A$10 million facility with SKIPTAN, to fund key clinical milestones. The company has elected to draw down only 50% of the committed amount initially, which it considers sufficient to complete all currently planned activities, including the ACTION3 Phase 3 trial of DMX-200 and the Phase 2 trial of DMX-652 in Acute Kidney Injury. The facility provides the option to secure up to A$50 million in total commitments on or before 31 March 2027, though Dimerix currently has no plans to access this additional funding. The loan agreements carry a 10% per annum interest rate, compounding annually, and are repayable by 17 January 2028. Dimerix has secured five commercial partners, generating A$81 million in upfront payments and the potential for a further A$237 million in development milestone payments.

Impact on stocks 1

Aging Population▲ · 1 stocks

Off-coverage companies 2

Dimerix LimitedPrivate▲ Positive
Capitalrelevance

Dimerix secured A$34 million in non-dilutive loan facilities to fund its ACTION3 Phase 3 and DMX-652 Phase 2 clinical milestones.

SKIPTAN Pty LtdPrivate▲ Positive
Capitalrelevance

SKIPTAN is part of the lender syndicate providing the previously announced A$10 million facility to Dimerix.

© 2026 MarketDXNews